[go: up one dir, main page]

DE60004974D1 - Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen - Google Patents

Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen

Info

Publication number
DE60004974D1
DE60004974D1 DE60004974T DE60004974T DE60004974D1 DE 60004974 D1 DE60004974 D1 DE 60004974D1 DE 60004974 T DE60004974 T DE 60004974T DE 60004974 T DE60004974 T DE 60004974T DE 60004974 D1 DE60004974 D1 DE 60004974D1
Authority
DE
Germany
Prior art keywords
neuro
poisoning
xenon
treatment
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60004974T
Other languages
English (en)
Other versions
DE60004974T3 (de
DE60004974T2 (de
Inventor
Christian Petzelt
J Kox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Air Products and Chemicals Inc
Original Assignee
AGA AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7900688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60004974(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AGA AB filed Critical AGA AB
Publication of DE60004974D1 publication Critical patent/DE60004974D1/de
Application granted granted Critical
Publication of DE60004974T2 publication Critical patent/DE60004974T2/de
Publication of DE60004974T3 publication Critical patent/DE60004974T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60004974T 1999-03-11 2000-03-08 Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen Expired - Lifetime DE60004974T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19910986A DE19910986C2 (de) 1999-03-11 1999-03-11 Verwendung von Xenon bei der Behandlung von Neurointoxikationen
DE19910986 1999-03-11
EP00910789A EP1158992B2 (de) 1999-03-11 2000-03-08 Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
PCT/EP2000/002025 WO2000053192A1 (en) 1999-03-11 2000-03-08 Use of xenon for treating neurointoxications

Publications (3)

Publication Number Publication Date
DE60004974D1 true DE60004974D1 (de) 2003-10-09
DE60004974T2 DE60004974T2 (de) 2004-07-22
DE60004974T3 DE60004974T3 (de) 2012-06-28

Family

ID=7900688

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19910986A Expired - Lifetime DE19910986C2 (de) 1999-03-11 1999-03-11 Verwendung von Xenon bei der Behandlung von Neurointoxikationen
DE60004974T Expired - Lifetime DE60004974T3 (de) 1999-03-11 2000-03-08 Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19910986A Expired - Lifetime DE19910986C2 (de) 1999-03-11 1999-03-11 Verwendung von Xenon bei der Behandlung von Neurointoxikationen

Country Status (29)

Country Link
US (3) US6559190B1 (de)
EP (1) EP1158992B2 (de)
JP (1) JP4954373B2 (de)
KR (1) KR100674407B1 (de)
CN (1) CN1170544C (de)
AR (1) AR022886A1 (de)
AT (1) ATE248599T1 (de)
AU (1) AU757361B2 (de)
BG (1) BG105889A (de)
BR (1) BR0010456A (de)
CA (1) CA2367136C (de)
CZ (1) CZ302864B6 (de)
DE (2) DE19910986C2 (de)
DK (1) DK1158992T3 (de)
EE (1) EE200100480A (de)
ES (1) ES2206202T5 (de)
HK (1) HK1048073B (de)
HU (1) HUP0201393A3 (de)
IL (2) IL145177A0 (de)
MD (1) MD2935C2 (de)
NO (1) NO20014379L (de)
PL (1) PL202941B1 (de)
PT (1) PT1158992E (de)
RS (1) RS49756B (de)
RU (1) RU2246949C2 (de)
SI (1) SI1158992T1 (de)
SK (1) SK285111B6 (de)
WO (1) WO2000053192A1 (de)
ZA (1) ZA200107291B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10045829A1 (de) * 2000-09-14 2002-04-04 Messer Griesheim Gmbh Volatile Anästhesiemittel mit Xenon
DE10054563A1 (de) * 2000-11-03 2002-05-16 Messer Griesheim Gmbh Verfahren und Vorrichtung zur Betonherstellung
US20020102211A1 (en) * 2000-12-07 2002-08-01 Renshaw Perry F. Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders
GB0209998D0 (en) 2002-05-01 2002-06-12 Protexeon Ltd Use
GB0210021D0 (en) * 2002-05-01 2002-06-12 Air Prod & Chem Ultrasonic gas analyser
ATE420650T1 (de) * 2002-06-12 2009-01-15 Air Liquide Deutschland Gmbh Cerebrale protektion mit einem xenonhaltigen gas
JP2006508040A (ja) * 2002-07-05 2006-03-09 メツサー グリースハイム ゲゼルシヤフト ミツト ベシユレンクテル ハフツング キセノンを含有するアジュバント
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US7337776B2 (en) 2002-08-20 2008-03-04 Aga Ab Methods for easing pain and anxiety from atrial or ventricular defibrillation
US7681572B2 (en) 2002-08-20 2010-03-23 Aga Ab Method and devices for administration of therapeutic gases
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
WO2005034966A1 (en) * 2003-10-10 2005-04-21 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
BRPI0415616A (pt) * 2003-10-21 2006-12-12 Aga Ab uso do xenÈnio para a prevenção da morte programada da célula
FR2863169B1 (fr) * 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
EP1552840A1 (de) * 2004-01-07 2005-07-13 Aga Ab Mischung aus Xenon und Kohlenmonoxyd zum Schutz von Zellen
US7070005B2 (en) * 2004-02-10 2006-07-04 Planetair Turf Products, Llc Soil aerator assembly
WO2006017524A2 (en) * 2004-08-02 2006-02-16 Olney John W Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems
WO2007075100A1 (en) * 2005-12-27 2007-07-05 Zakrytoe Aktsionernoe Obshchestvo 'atom-Med Center' Method for treating drug dependence
EP1980260A1 (de) * 2007-04-10 2008-10-15 Nicholas Peter Franks Verwendung hyperbarischer Bedingungen zur Bereitstellung von Neuroprotektion
WO2008132239A1 (en) * 2007-04-30 2008-11-06 Nnoxe Pharmaceutiques Inc Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
WO2010035074A1 (en) * 2008-09-25 2010-04-01 Nnoxe Pharmaceutiques Inc Use of nitrous oxide, argon, xenon, helium, or neon, for the manufacture of a pharmaceutical composition for treating ischemic insults in patients who cannot be treated with thrombolytic agents
FR2952305B1 (fr) * 2009-11-10 2012-04-27 Air Liquide Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
WO2011081612A1 (ru) * 2009-12-31 2011-07-07 Bondarenko Vitaliy Leonidovich Применение криптона или ксенона в качестве противовирусного средства
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
FR2960779A1 (fr) 2010-06-08 2011-12-09 Air Liquide Medicament gazeux inhalable a base de krypton contre les deficiences ou defaillances d'organes peripheriques
FR2964036B1 (fr) 2010-08-24 2013-04-12 Air Liquide Medicament gazeux inhalable a base de krypton pour le traitement des neuro-intoxications
CA2824948C (en) * 2011-02-07 2020-06-02 Rich Products Corporation Method for preserving cells and cell cultures
FR2975597B1 (fr) * 2011-05-24 2013-12-27 Air Liquide Utilisation de neon pour le traitement des neuro-intoxications, notamment des maladies enurodegeneratives et demyelinisantes
TWI610622B (zh) 2011-09-26 2018-01-11 瑞奇科技控股股份有限公司 活組織保存方法
RU2489154C1 (ru) * 2012-05-31 2013-08-10 Сергей Александрович Наумов Способ лечения вирусных гепатитов
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
FR2996459B1 (fr) 2012-10-09 2015-02-06 Air Liquide Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996458B1 (fr) * 2012-10-09 2015-02-27 Air Liquide Utilisation de xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996457B1 (fr) 2012-10-09 2019-11-29 L'air Liquide,Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Utilisation d'argon pour prevenir ou traiter les consequences neurologiques d'un choc septique
WO2014093277A1 (en) 2012-12-11 2014-06-19 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
EP2968126B1 (de) 2013-03-15 2022-04-06 The Board of Regents of The University of Texas System Edelgasreiche flüssigkeiten sowie verfahren zu deren herstellung und verwendung
FR3007983B1 (fr) * 2013-07-08 2015-06-26 Air Liquide Association de xenon et d'un antagoniste des recepteurs nmda pour lutter contre une maladie neurodegenerative
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central
FR3027226B1 (fr) * 2014-10-17 2017-12-08 L'air Liquide Sa Pour L'etude Et L'exploitation Des Procedes Georges Claude Medicament pour traiter une maladie liee a un dysfonctionnement de la transmission synaptique dopaminergique
CN107921008A (zh) * 2015-06-23 2018-04-17 诺比利斯治疗学公司 使用惰性气体组合物的治疗性免疫调节
WO2017083373A1 (en) * 2015-11-09 2017-05-18 The Mclean Hospital Corporation Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
US20170341980A1 (en) * 2016-05-31 2017-11-30 Noblis Therapeutics, Inc. Noble gas neuroprotection and neuroregeneration from treatment related neurotoxicity
US10485825B2 (en) * 2016-08-29 2019-11-26 Nobilis Therapeutics, Inc. Prevention of pregnancy complications by noble gas administration
CN110337297A (zh) * 2016-10-31 2019-10-15 诺比利斯治疗学公司 通过给予含有惰性气体的混合物来治疗焦虑症和增强抗焦虑介入治疗
CN107569509B (zh) * 2017-02-22 2018-09-21 滨州医学院 氙或氙气体混合物在制备治疗癫痫的制剂中的用途
CN108986622A (zh) * 2018-08-16 2018-12-11 广州迈普再生医学科技股份有限公司 一种颅内血肿微创穿刺清除术培训装置及其制备方法
RU2712804C1 (ru) * 2018-08-29 2020-01-31 Жовнерчук Инна Юрьевна Способ коррекции функционального состояния человека в замкнутом пространстве

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5228434A (en) * 1991-07-16 1993-07-20 Praxair Technology, Inc. Mixture for anesthesia
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
US5357959A (en) * 1993-04-16 1994-10-25 Praxair Technology, Inc. Altered dipole moment magnetic resonance imaging method
US5846556A (en) * 1996-06-14 1998-12-08 Brooks; Bradley S. Inhalant for reducing stress and method of use
IT1286058B1 (it) * 1996-10-29 1998-07-07 Siad Societa Italiana Acetilen Procedimento e apparecchiatura per la purificazione e recupero dello xeno e altri gas nobili in sistemi anestetici
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19823606C2 (de) * 1998-05-27 2002-02-28 Draeger Medical Ag Verwendung von Perfluorcarbone in einem Atemgasgemisch sowie die Vorrichtung
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
ATE248599T1 (de) 2003-09-15
AU757361B2 (en) 2003-02-20
EE200100480A (et) 2002-12-16
BR0010456A (pt) 2002-08-27
NO20014379L (no) 2001-11-07
AR022886A1 (es) 2002-09-04
ES2206202T5 (es) 2012-05-22
PL350618A1 (en) 2003-01-27
PT1158992E (pt) 2004-01-30
WO2000053192A1 (en) 2000-09-14
HK1048073A1 (en) 2003-03-21
KR20010108338A (ko) 2001-12-07
HUP0201393A3 (en) 2002-10-28
IL145177A0 (en) 2002-06-30
BG105889A (bg) 2002-04-30
YU65401A (sh) 2004-07-15
RU2246949C2 (ru) 2005-02-27
JP2002538209A (ja) 2002-11-12
CA2367136A1 (en) 2000-09-14
IL145177A (en) 2006-10-31
ZA200107291B (en) 2003-02-26
DE60004974T3 (de) 2012-06-28
CA2367136C (en) 2008-05-13
HK1048073B (zh) 2005-06-03
CN1359296A (zh) 2002-07-17
US20030180375A1 (en) 2003-09-25
MD20010349A (en) 2002-02-28
DE19910986C2 (de) 2001-06-07
CN1170544C (zh) 2004-10-13
US6559190B1 (en) 2003-05-06
SI1158992T1 (en) 2004-02-29
ES2206202T3 (es) 2004-05-16
JP4954373B2 (ja) 2012-06-13
SK285111B6 (sk) 2006-06-01
EP1158992B2 (de) 2012-02-01
US20070110821A1 (en) 2007-05-17
US8143317B2 (en) 2012-03-27
CZ302864B6 (cs) 2011-12-21
HUP0201393A2 (en) 2002-09-28
CZ20013234A3 (cs) 2002-06-12
MD2935C2 (ro) 2006-08-31
MD2935B2 (en) 2005-12-31
EP1158992A1 (de) 2001-12-05
EP1158992B1 (de) 2003-09-03
KR100674407B1 (ko) 2007-01-26
SK12792001A3 (sk) 2002-07-02
RS49756B (sr) 2008-04-04
DK1158992T3 (da) 2003-12-29
DE60004974T2 (de) 2004-07-22
AU3287500A (en) 2000-09-28
NO20014379D0 (no) 2001-09-10
PL202941B1 (pl) 2009-08-31
DE19910986A1 (de) 2000-09-21

Similar Documents

Publication Publication Date Title
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE69921941D1 (de) Verfahren zur Herstellung von pharmazeutischen Wirkstoffpartikeln
NO20006630L (no) Farmasöytisk sammensetning for behandlingen av diabetes
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE59810581D1 (de) Verfahren zur Herstellung feinstrukturierter medizintechnischer Implantate
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60019747D1 (de) Verfahren zur herstellung von fluorolefinen
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69716223D1 (de) Vorrichtung zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung
DE50012014D1 (de) Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69901243D1 (de) Artikulator zur herstellung von zahnärztlichen prothesen
DE69937692D1 (de) Arzneimittel zur behandlung der hemicrania
DE69738320D1 (de) Verwendung von pyrolidin-derivaten zur herstellung von arzneimitteln zur behandlung von drogenmissbrauch
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: AIR PRODUCTS AND CHEMICALS, INC., ALLENTOWN, P, US

8328 Change in the person/name/address of the agent

Representative=s name: SCHWABE, SANDMAIR, MARX, 81677 MUENCHEN

R102 Epo decision maintaining patent in amended form now final

Ref document number: 1158992

Country of ref document: EP

R102 Epo decision maintaining patent in amended form now final

Ref document number: 1158992

Country of ref document: EP

Effective date: 20120201

R082 Change of representative

Ref document number: 1158992

Country of ref document: EP

Representative=s name: WSL PATENTANWAELTE PARTNERSCHAFTSGESELLSCHAFT, 651

Ref document number: 1158992

Country of ref document: EP

Representative=s name: WSL PATENTANWAELTE PARTNERSCHAFTSGESELLSCHAFT, DE